[CAS NO. 181629-93-6] SB228357
PRODUCTS SPECIFICATIONS [181629-93-6]
DESCRIPTION [181629-93-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 431.38 |
| Molecular Formula | C22H17F4N3O2 |
| SMILES | O=C(N1CCC2=C1C=C(C(F)(F)F)C(OC)=C2)NC3=CC(C4=CC=CN=C4)=CC(F)=C3 |
Summary
IC50 & Target
|
5-HT 2A Receptor 6.9 (pKi) |
5-HT 2C Receptor 9 (pKi) |
5-HT 2B Receptor 8 (pKi) |
In Vivo
SB228357 (0-10 mg/kg; oral administration; for 90 minutes; male Sprague Dawley rats) treatment significantly reverses Haloperidol-induced catalepsy [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Sprague Dawley rats (200-250 g) injected with Haloperidol [2] |
| Dosage: | 0 mg/kg, 0.32 mg/kg, 1 mg/kg, 3.2 mg/kg, 10 mg/kg |
| Administration: | Oral administration; for 90 minutes |
| Result: | Significantly reversed Haloperidol-induced catalepsy. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
References
- [1] Bromidge SM, et al. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/a
- [2] Reavill C, et al. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.
